Kintegral Advisory’s PTC Therapeutics PTCT Stock Holding History

Kintegral Advisory’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,293	Closed	-$294K	–	264
2023 Q1	$294K	Buy	+2,293	New	+$105K	0.04%	245

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Kintegral Advisory's PTCT Position: Q2 2023 in Review

Kintegral Advisory sold out of PTC Therapeutics (PTCT) in Q2 2023, closing a stake of 2,293 shares — an estimated $294K sold.

Kintegral Advisory first reported a position in PTCT in Q1 2023 and held it in 1 quarter. The position peaked at $294K in Q1 2023. 204 funds tracked by Wall St. Rank hold PTCT as of Q2 2023.

Kintegral Advisory reported no remaining PTC Therapeutics position as of Q2 2023 after selling out during the quarter.
Kintegral Advisory sold 2,293 PTC Therapeutics shares in Q2 2023, an estimated $294K.
Kintegral Advisory first reported a position in PTC Therapeutics in Q1 2023 and held it in 1 quarter.
Kintegral Advisory's PTC Therapeutics position peaked at $294K in Q1 2023.
204 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2023.

Based on Kintegral Advisory's 13F filing for Q2 2023, filed 2 Aug 2023.